RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @CD_AACR: Just published #OnlineFirst! Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR e…
RT @CD_AACR: Just published #OnlineFirst! Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR e…
RT @CD_AACR: Just published #OnlineFirst! Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR e…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @geoff_oxnard: Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces g…
RT @ElizSMcKenna: Now online in @CD_AACR: another agent with potential activity in EGFR exon 20 NSCLC - follows amivantamab's Breakthrough…
Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces greater response than poziotinib or cetuximab in vivo. 2 dramatic pt responses shown too! More data soon at #ASCO20: https://t.co/a4
RT @ElizSMcKenna: Now online in @CD_AACR: another agent with potential activity in EGFR exon 20 NSCLC - follows amivantamab's Breakthrough…
Now online in @CD_AACR: another agent with potential activity in EGFR exon 20 NSCLC - follows amivantamab's Breakthrough Therapy Designation in March.
RT @CD_AACR: Just published #OnlineFirst! Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR e…
Just published #OnlineFirst! Antitumor activity of amivantamab, an #EGFR-cMET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven non–small cell #LungCancer. #NSCLC https://t.co/hVFkmUyiXh